120 related articles for article (PubMed ID: 23567961)
61. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.
Frett B; McConnell N; Smith CC; Wang Y; Shah NP; Li HY
Eur J Med Chem; 2015 Apr; 94():123-31. PubMed ID: 25765758
[TBL] [Abstract][Full Text] [Related]
62. Gene expression-based screening for inhibitors of PDGFR signaling.
Antipova AA; Stockwell BR; Golub TR
Genome Biol; 2008; 9(3):R47. PubMed ID: 18312689
[TBL] [Abstract][Full Text] [Related]
63. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
64. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
65. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors.
Huang M; Li Z; Li D; Walker S; Greenan C; Kennedy R
Bioorg Med Chem Lett; 2013 May; 23(10):3044-50. PubMed ID: 23562057
[TBL] [Abstract][Full Text] [Related]
66. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.
Duong-Ly KC; Devarajan K; Liang S; Horiuchi KY; Wang Y; Ma H; Peterson JR
Cell Rep; 2016 Feb; 14(4):772-781. PubMed ID: 26776524
[TBL] [Abstract][Full Text] [Related]
67. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.
Deng X; Zhou W; Weisberg E; Wang J; Zhang J; Sasaki T; Nelson E; Griffin JD; Jänne PA; Gray NS
Bioorg Med Chem Lett; 2012 Jul; 22(14):4579-84. PubMed ID: 22727638
[TBL] [Abstract][Full Text] [Related]
68. Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
Qin M; Tian Y; Sun X; Yu S; Xia J; Gong P; Zhang H; Zhao Y
Eur J Med Chem; 2017 Oct; 139():492-502. PubMed ID: 28826084
[TBL] [Abstract][Full Text] [Related]
69. Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor.
Wilson EA; Russu WA; Shallal HM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1781-1784. PubMed ID: 29678462
[TBL] [Abstract][Full Text] [Related]
70. Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2.
Qi B; Xu X; Yang Y; Zhou Y; Chen T; Gong G; Yue X; Xu X; Hu L; He H
Bioorg Med Chem; 2019 May; 27(10):2127-2139. PubMed ID: 30940564
[TBL] [Abstract][Full Text] [Related]
71. Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics.
Horbert R; Pinchuk B; Johannes E; Schlosser J; Schmidt D; Cappel D; Totzke F; Schächtele C; Peifer C
J Med Chem; 2015 Jan; 58(1):170-82. PubMed ID: 25007344
[TBL] [Abstract][Full Text] [Related]
72. Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity.
Fernandes ÍA; Braga Resende D; Ramalho TC; Kuca K; da Cunha EFF
Molecules; 2020 Apr; 25(7):. PubMed ID: 32283751
[TBL] [Abstract][Full Text] [Related]
73. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Nagaraj H; Williams M; Wang H; Lee A; Sun E; Teo EL; Tan E; Goh KC; Dymock B
J Mol Model; 2013 Jan; 19(1):119-30. PubMed ID: 22820730
[TBL] [Abstract][Full Text] [Related]
74. Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.
Liu G; Abraham S; Liu X; Xu S; Rooks AM; Nepomuceno R; Dao A; Brigham D; Gitnick D; Insko DE; Gardner MF; Zarrinkar PP; Christopher R; Belli B; Armstrong RC; Holladay MW
Bioorg Med Chem Lett; 2015 Sep; 25(17):3436-41. PubMed ID: 26208887
[TBL] [Abstract][Full Text] [Related]
75. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
[TBL] [Abstract][Full Text] [Related]
76. Identification and further development of potent TBK1 inhibitors.
Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906
[TBL] [Abstract][Full Text] [Related]
77. Marine derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors.
Pinchuk B; Johannes E; Gul S; Schlosser J; Schaechtele C; Totzke F; Peifer C
Mar Drugs; 2013 Aug; 11(9):3209-23. PubMed ID: 24065162
[TBL] [Abstract][Full Text] [Related]
78. Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.
Chang Y; Zhu D; Guo H; Yin X; Ding K; Li Z
Chembiochem; 2019 Jul; 20(14):1783-1788. PubMed ID: 30942519
[TBL] [Abstract][Full Text] [Related]
79. Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.
Bensinger D; Stubba D; Cremer A; Kohl V; Waßmer T; Stuckert J; Engemann V; Stegmaier K; Schmitz K; Schmidt B
J Med Chem; 2019 Mar; 62(5):2428-2446. PubMed ID: 30742435
[TBL] [Abstract][Full Text] [Related]
80. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
Baladi T; Abet V; Piguel S
Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
